Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

0.4485 -0.0115 (-2.50%)
Streaming Delayed Price Updated: 12:31 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 204,894
Open 0.4700
Bid (Size) 0.4480 (1)
Ask (Size) 0.4542 (2)
Prev. Close 0.4600
Today's Range 0.4421 - 0.4700
52wk Range 0.4351 - 1.625
Shares Outstanding 1,535,299,242
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working... 
Via Newsfile

Performance

YTD
-28.1%
-28.1%
1 Month
-23.0%
-23.0%
3 Month
-25.2%
-25.2%
6 Month
-57.3%
-57.3%
1 Year
-69.5%
-69.5%

More News

Read More
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Via Newsfile
Exposures Product Safety
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Via Newsfile
Topics Initial Public Offering
Exposures Securities Market
Demystifying Adaptimmune Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
An Overview of Adaptimmune Therapeutics's Earnings
Via Benzinga
The Latest Analyst Ratings For Adaptimmune Therapeutics
Via Benzinga
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Via Newsfile
Adaptimmune Reports Q3 2024 Financial and Business Updates
Via Newsfile
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Via Newsfile
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Via Newsfile
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
Via Newsfile
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
From Virtual Investor Conferences
Via GlobeNewswire
Adaptimmune to Participate in Two Bank Conferences this September
Via Newsfile
ADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Adaptimmune Reports Q2 2024 Financial and Business Updates
Via Newsfile
Exposures Product Safety
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
Via Benzinga
Exposures Product Safety
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
From Adaptimmune Therapeutics plc
Via Business Wire
3 Biotech Moonshots With Imminent Catalyst Potential
Via InvestorPlace
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
Via Newsfile
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
Via AB Newswire
Exposures Product Safety
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga

Frequently Asked Questions

Is Adaptimmune Therapeutics plc - American Depositary Shares publicly traded?
Yes, Adaptimmune Therapeutics plc - American Depositary Shares is publicly traded.
What exchange does Adaptimmune Therapeutics plc - American Depositary Shares trade on?
Adaptimmune Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Adaptimmune Therapeutics plc - American Depositary Shares?
The ticker symbol for Adaptimmune Therapeutics plc - American Depositary Shares is ADAP on the Nasdaq Stock Market
What is the current price of Adaptimmune Therapeutics plc - American Depositary Shares?
The current price of Adaptimmune Therapeutics plc - American Depositary Shares is 0.4485
When was Adaptimmune Therapeutics plc - American Depositary Shares last traded?
The last trade of Adaptimmune Therapeutics plc - American Depositary Shares was at 03/19/25 12:31 PM ET
What is the market capitalization of Adaptimmune Therapeutics plc - American Depositary Shares?
The market capitalization of Adaptimmune Therapeutics plc - American Depositary Shares is 688.58M
How many shares of Adaptimmune Therapeutics plc - American Depositary Shares are outstanding?
Adaptimmune Therapeutics plc - American Depositary Shares has 689M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.